文献速递肝病消化道肿瘤与早癌

丙型肝炎病毒相关肝细胞癌未治疗患者存在种族和民族差异,但获得持续病毒学应答者则无此差异

Racial and ethnic disparities in untreated patients with hepatitis C virus-related hepatocellular carcinoma but not in those with sustained virologic response.
PubMed 文献 · Aliment Pharmacol Ther · 2024-01-03

这项回顾性队列研究分析了美国和亚洲中心6069例HCV相关HCC患者,发现直接抗病毒药物(DAA)治疗率在黑人患者中最低(18.7%),未治疗或未获SVR者10年生存率存在种族差异,而获得SVR者生存无显著差异;结论认为DAA治疗率不理想,HCV治愈后种族差异消失,需早期诊断和改善治疗可及性。

要点

  • 黑人患者DAA治疗率最低(18.7%),亚裔35.9%、白人34.9%、西班牙裔30.3%(p<0.0001)。
  • 未治疗或未获SVR者10年生存率:亚裔35.4%、西班牙裔27.5%、白人19.3%、黑人14.0%(p<0.0001)。
  • 获得SVR者生存率无统计学显著差异(p=0.44)。

核心结论

  • DAA治疗率不理想;种族和民族差异在HCV治愈后消失;所有HCV感染患者都需要早期诊断和改善治疗可及性。

研究设计与样本

  • 回顾性队列研究,纳入美国和亚洲中心的6069例HCV相关HCC患者(亚裔54.2%、白人30.1%、黑人8.5%、西班牙裔7.3%)。

主要发现

  • 白人、黑人、西班牙裔和亚裔患者的平均年龄分别为61、60、59和68岁。
  • 黑人患者最可能具有巴塞罗那临床肝癌D期、血管侵犯和远处转移(分别为23% vs 5%-15%、20% vs 10%-17%和10% vs 5%-7%,所有p<0.0001)。
  • DAA治疗率:亚裔35.9%、白人34.9%、西班牙裔30.3%、黑人18.7%(p<0.0001)。
  • 未治疗或未获SVR者10年生存率:亚裔35.4%、西班牙裔27.5%、白人19.3%、黑人14.0%(p<0.0001);获得SVR者无统计学显著差异(p=0.44)。
  • 多变量分析中,与白人相比,西班牙裔(aHR:0.68,p=0.26)或黑人(aHR:1.18,p=0.60)与生存无统计学显著关联;亚裔美国人(aHR:0.24,p=0.001;非美国亚裔:aHR:0.66,p=0.05)和SVR(aHR:0.30,p<0.0001)与生存有显著关联。

临床怎么用

  • 原文结论指出所有HCV感染患者都需要早期诊断和改善HCV治疗可及性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Racial and ethnic disparities exist for hepatitis C virus (HCV) treatment and hepatocellular carcinoma (HCC) survival. AIM: To evaluate the impact of HCV treatment on such disparities. METHODS: In a retrospective cohort study, we analysed 6069 patients with HCV-related HCC (54.2% Asian, 30.1% White, 8.5% Black, and 7.3% Hispanic) from centres in the United States and Asia. RESULTS: The mean age was 61, 60, 59 and 68, respectively, for White, Black, Hispanic and Asian patients. Black patients were most likely to have Barcelona Clinic Liver Cancer stage D, vascular invasion and distant metastasis (23% vs. 5%-15%, 20% vs. 10%-17% and 10% vs. 5%-7%, respectively; all p < 0.0001). Treatment rate with direct-acting antiviral agents (DAA) was 35.9% for Asian, 34.9% for White, 30.3% for Hispanic (30.3%), and 18.7% for Black patients (p < 0.0001). Among those untreated or without sustained virologic response (SVR), 10-year survival rates were 35.4, 27.5, 19.3 and 14.0, respectively, for Asian, Hispanic, White and Black patients (p < 0.0001). There were no statistically significant differences among those with SVR (p = 0.44). On multivariable analysis adjusted for relevant confounders, there was no statistically significant association between survival and being Hispanic (aHR: 0.68, p = 0.26) or Black (aHR: 1.18, p = 0.60) versus White. There was a significant association between being Asian American and survival (aHR: 0.24, p = 0.001; non-U.S. Asian: aHR: 0.66, p = 0.05), and for SVR (aHR: 0.30, p < 0.0001). CONCLUSION: DAA treatment rates were suboptimal. Racial and ethnic disparities resolved with HCV cure. Early diagnosis and improved access to HCV treatment is needed for all patients with HCV infection.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Park JE, Nguyen VH, Tsai PC, et al. Racial and ethnic disparities in untreated patients with hepatitis C virus-related hepatocellular carcinoma but not in those with sustained virologic response. Aliment Pharmacol Ther. 2024. PMID: 38173278. doi:10.1111/apt.17863

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。